TESAMORELIN RESEARCH UPDATES
Tesamorelin Research Updates: Recent Notes
A newer formulation and continued metabolic research
Tesamorelin research updates mostly concern formulation changes and continued interest in its metabolic effects, rather than new approved uses.
Recent Formulation Note
The EGRIFTA WR formulation was approved in 2025 as a new presentation that reduces how often a vial must be reconstituted. It did not change the approved medical indication.
Source: FDA approval letter for EGRIFTA WR.
What to Watch
- Any research extending beyond the approved indication (e.g., liver-fat studies) — which so far has not created new approved uses.
- Formulation and access changes within the EGRIFTA family.
Frequently Asked Questions
What's the most recent tesamorelin development?
A newer EGRIFTA formulation (EGRIFTA WR) approved in 2025, without changing the approved use.
Have new approved uses been added?
Not as of this review; research outside the approved indication remains investigational.
The Bottom Line
Tesamorelin research updates are mainly about formulation and ongoing (not-yet-approved) metabolic research.
This article is for general educational purposes only. It is not medical advice and should not be used to diagnose, treat, or make decisions about any health condition or medication.
Primary Sources
- FDA approval letter for EGRIFTA WR
- FDA prescribing information for EGRIFTA WR
Wellness should feel clear, personal, and supported.
Start with education, ask the right questions, and take the next step with confidence.
Get in touch →